IN2014DN10558A - - Google Patents

Download PDF

Info

Publication number
IN2014DN10558A
IN2014DN10558A IN10558DEN2014A IN2014DN10558A IN 2014DN10558 A IN2014DN10558 A IN 2014DN10558A IN 10558DEN2014 A IN10558DEN2014 A IN 10558DEN2014A IN 2014DN10558 A IN2014DN10558 A IN 2014DN10558A
Authority
IN
India
Prior art keywords
amino acid
acid sequence
polypeptide
salt
cell epitope
Prior art date
Application number
Inventor
Roderick Peter Hafner
Paul Laidler
Pascal Hickey
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46582267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN10558(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of IN2014DN10558A publication Critical patent/IN2014DN10558A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations

Abstract

Pharmaceutical formulations which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporiumgenus comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a)a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT(Alt28; SEQ ID NO: 101) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; (b)a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR(Alt34A; SEQ ID NO: 107) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; (d)a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ(Alt13A; SEQ ID NO: 83) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; (e)a polypeptide comprising the amino acid sequence of SLGFNIKATNGGTLD(Alt01A; SEQ ID NO: 60)or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; (f) a polypeptide comprising the amino acid sequence of SAKRMKVAFKLDIEK(Alt06; SEQ ID NO: 72) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; (g)a polypeptide comprising the amino acid sequence of DITYVATATLPNYCR(SEQ ID NO: 111) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; and (h)a polypeptide comprising the amino acid sequence of GWGVMVSHRSGET(Alt14;SEQ ID NO: 84) or a T cell epitope containing variant sequence derived from said amino acid sequence or a said salt thereof; wherein a T cell epitope containing variant sequence of a said amino acid sequence is said amino acid sequence having up to seven amino acid modifications each of which is independently a deletion substitution or insertion and each polypeptide is up to 30 amino acids in length.
IN10558DEN2014 2012-06-01 2013-05-30 IN2014DN10558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1209868.7A GB201209868D0 (en) 2012-06-01 2012-06-01 Alternaria peptides
PCT/GB2013/051439 WO2013179043A1 (en) 2012-06-01 2013-05-30 Alternaria peptides

Publications (1)

Publication Number Publication Date
IN2014DN10558A true IN2014DN10558A (en) 2015-08-21

Family

ID=46582267

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10558DEN2014 IN2014DN10558A (en) 2012-06-01 2013-05-30

Country Status (17)

Country Link
US (1) US20150098969A1 (en)
EP (1) EP2855515A1 (en)
JP (1) JP2015520771A (en)
KR (1) KR20150028788A (en)
CN (1) CN104507959A (en)
AU (1) AU2013269326A1 (en)
BR (1) BR112014029856A2 (en)
CA (1) CA2875130A1 (en)
CL (1) CL2014003290A1 (en)
EA (1) EA201492268A1 (en)
GB (2) GB201209868D0 (en)
HK (1) HK1201752A1 (en)
IL (1) IL235840A0 (en)
IN (1) IN2014DN10558A (en)
MX (1) MX2014014461A (en)
SG (1) SG11201407975TA (en)
WO (1) WO2013179043A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014195382A1 (en) * 2013-06-05 2014-12-11 Alergenetica Sl T cell epitopes derived from alt a 1 or alt a 5 for the treatment of alternaria alternata allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT400723B (en) * 1993-08-27 1996-03-25 Biomay Prod & Handel RECOMBINANT ALTERNARIA ALTERNATA ALLERGENS
JP2007176953A (en) * 1996-03-10 2007-07-12 Meiji Milk Prod Co Ltd Peptide immunotherapeutic agent for treating allergic disease
JP2003116556A (en) * 2001-10-09 2003-04-22 Nippon Zenyaku Kogyo Kk Therapeutic agent for allergic dermatitis
AT503690A1 (en) * 2006-06-09 2007-12-15 Biomay Ag HYPOALLERGENIC MOLECULES
EP2397154B1 (en) * 2007-08-15 2015-07-15 Circassia Limited Peptides for desensibilization against allergens
GB0821806D0 (en) * 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
US20130259884A1 (en) * 2010-09-24 2013-10-03 Alergenetica Sl Peptides

Also Published As

Publication number Publication date
GB201209868D0 (en) 2012-07-18
MX2014014461A (en) 2015-02-10
BR112014029856A2 (en) 2017-07-25
EP2855515A1 (en) 2015-04-08
JP2015520771A (en) 2015-07-23
KR20150028788A (en) 2015-03-16
HK1201752A1 (en) 2015-09-11
IL235840A0 (en) 2015-01-29
WO2013179043A1 (en) 2013-12-05
SG11201407975TA (en) 2015-01-29
AU2013269326A1 (en) 2014-12-18
US20150098969A1 (en) 2015-04-09
EA201492268A1 (en) 2015-05-29
CL2014003290A1 (en) 2015-05-22
CA2875130A1 (en) 2013-12-05
GB2517871A (en) 2015-03-04
CN104507959A (en) 2015-04-08

Similar Documents

Publication Publication Date Title
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
MX342291B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
IN2014KN01713A (en)
WO2018067217A3 (en) Compositions comprising pedf-derived short peptides and uses thereof
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
NZ602845A (en) Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof
NZ628756A (en) Immunogens for hiv vaccination
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
IN2014DN06920A (en)
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
IN2015DN00585A (en)
EA033437B1 (en) Fc GAMMA RECEPTOR IIB AND USE THEREOF FOR TREATING OR PREVENTING INFLAMMATORY AND/OR AUTOIMMUNE DISEASES
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
IN2014DN09963A (en)
EA201590601A1 (en) APPLICATION OF PEDF-DERIVED POLYPEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS
MY187334A (en) Xylanase
PH12015502005A1 (en) New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
EA201690966A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA
NZ592461A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
IN2014DN10558A (en)
MY166516A (en) Tomm34 peptides and vaccines including the same
GB201018125D0 (en) Peptide